
Clyde W Yancy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1087034/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association Between Neighborhood-Level Poverty and Incident Atrial Fibrillation: a Retrospective Cohort Study. Journal of General Internal Medicine, 2022, 37, 1436-1443.	1.3	6
2	Reimagining educational equity through strategic alliance partnerships in response to the USA STEM-M diversity gap. Health Promotion International, 2022, 37, .	0.9	5
3	Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure, 2022, 28, 93-112.	0.7	15
4	Identifying Treatments for Stage C2 Heart Failure. JAMA Cardiology, 2022, 7, 34.	3.0	5
5	Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. American Heart Journal, 2022, 244, 135-148.	1.2	10
6	Sex Differences in Heart Failure. Journal of Cardiac Failure, 2022, 28, 477-498.	0.7	62
7	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 554-563.	0.7	4
8	Race Bias in Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2022, 7, 158.	3.0	0
9	Development and Validation of a Long-Term Incident Heart Failure Risk Model. Circulation Research, 2022, 130, 200-209.	2.0	9
10	Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines – heart failure participating centers. American Heart Journal, 2022, 246, 1-11.	1.2	0
11	Healthâ€Related Quality of Life in Older Patients With Advanced Heart Failure: Findings From the SUSTAINâ€IT Study. Journal of the American Heart Association, 2022, 11, e024385.	1.6	7
12	Propensity Score-Matched Comparison of Right Ventricular Strain in Women and Men Before and After Left Ventricular Assist Device Implantation. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2022, 17, 102-110.	0.4	2
13	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With HeartÂFailure and Diabetes. JACC: Heart Failure, 2022, 10, 198-210.	1.9	16
14	The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study. Contemporary Clinical Trials, 2022, 115, 106732.	0.8	2
15	Distribution of 10- and 30-Year Predicted Risks for Heart Failure in the US Population: National Health and Nutrition Examination Surveys 2015 to 2018. Circulation: Heart Failure, 2022, , CIRCHEARTFAILURE121009351.	1.6	1
16	Heart failure quality of care and <scp>inâ€hospital</scp> outcomes during the <scp>COVID</scp> â€19 pandemic: findings from the Get With The <scp>Guidelinesâ€Heart</scp> Failure registry. European Journal of Heart Failure, 2022, 24, 1117-1128.	2.9	16
17	Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials. JAMA Cardiology, 2022, 7, 540.	3.0	20
18	Sex-Based Differences in HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 1530-1541.	1.2	22

#	Article	IF	CITATIONS
19	Tipping the scale toward a more accurate and equitable assessment of heart failure with reduced ejection fraction pharmacotherapy eligibility: a call to incorporate cystatin C in estimating glomerular filtration rate. European Journal of Heart Failure, 2022, 24, 867-870.	2.9	3
20	Who Is at Risk for Heart Failure?. JAMA Cardiology, 2022, , .	3.0	1
21	Reducing disparities in cardiovascular health in African Americans through integrated cardiovascular sleep care in outpatient setting. SLEEP Advances, 2022, 3, .	0.1	0
22	Resident Physician Wellness Postpandemic. JAMA - Journal of the American Medical Association, 2022, 327, 2077.	3.8	1
23	Contemporary Trends and Comparison of Racial Differences in Hospitalizations of Adults With Congenital Heart Disease. American Journal of Cardiology, 2022, , .	0.7	0
24	Blood Pressure and Glycemic Control Among Ambulatory US Adults With Heart Failure: National Health and Nutrition Examination Survey 2001 to 2018. Circulation: Heart Failure, 2022, 15, 101161CIRCHEARTFAILURE121009229.	1.6	5
25	Multiparametric Cardiac Magnetic Resonance Imaging Detects Altered Myocardial Tissue and Function in Heart Transplantation Recipients Monitored for Cardiac Allograft Vasculopathy. Journal of Cardiovascular Imaging, 2022, 30, 263.	0.2	3
26	Why Continuity of STEM-Medicine Participation Matters: Exploring a Culture of Transformation and the Optimization of College Socialization. Journal of Advanced Academics, 2022, 33, 433-468.	0.5	3
27	Replacing Race With Social Determinants of Health in Risk Prediction—Getting It Right. JAMA Cardiology, 2022, 7, 856.	3.0	5
28	Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19: Findings From the American Heart Association's COVID-19 Cardiovascular Disease Registry. Circulation, 2021, 143, 2332-2342.	1.6	113
29	Temporal trends in risk profiles among patients hospitalized for heart failure. American Heart Journal, 2021, 232, 154-163.	1.2	8
30	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. JAMA Cardiology, 2021, 6, 267.	3.0	22
31	Trial characteristics associated with underâ€enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review. European Journal of Heart Failure, 2021, 23, 15-24.	2.9	74
32	Association of cigarette smoking and adverse events in left ventricular assist device patients. International Journal of Artificial Organs, 2021, 44, 181-187.	0.7	2
33	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2021, 325, 39.	3.8	65
34	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2021, 69, 1309-1318.	1.3	4
35	United Network for Organ Sharing 2018 Heart Transplant Reallocation Policy. JAMA Cardiology, 2021, 6, 168.	3.0	4
36	Risk-Based Approach for the Prediction and Prevention of Heart Failure. Circulation: Heart Failure, 2021, 14, e007761.	1.6	19

#	Article	IF	CITATIONS
37	Evaluation of Risk-Adjusted Home Time After Hospitalization for Heart Failure as a Potential Hospital Performance Metric. JAMA Cardiology, 2021, 6, 169.	3.0	17
38	Recalibrating the Use of Race in Medical Research. JAMA - Journal of the American Medical Association, 2021, 325, 623.	3.8	187
39	To be, or not to be BAME, in the time of COVID-19: does it matter?. Heart, 2021, 107, 692-693.	1.2	1
40	Heart Failure Risk Distribution and Trends in the United States Population, NHANES 1999-2016. American Journal of Medicine, 2021, 134, e153-e164.	0.6	16
41	Reporting Genetic Markers and the Social Determinants of Health in Clinical Cardiovascular Research <i>—</i> It Is Time to Recalibrate the Use of Race. JAMA Cardiology, 2021, 6, 400.	3.0	5
42	Universal Definition and Classification of Heart Failure: Is It universal? Does It Define Heart Failure?. Journal of Cardiac Failure, 2021, 27, 509-511.	0.7	9
43	Distribution and Correlates of Incident Heart Failure Risk in South Asian Americans: The MASALA Study. Journal of Cardiac Failure, 2021, 27, 1214-1221.	0.7	0
44	Is the Left Ventricular Ejection Fraction Measurement Still Preeminent?—New Measures to Quantify Subclinical Systolic Dysfunction. JAMA Cardiology, 2021, 6, 521.	3.0	4
45	The Journey Toward Health Equity: Are We Nearing an Abyss or Ascending a Peak?. Circulation, 2021, 143, 2327-2328.	1.6	4
46	Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults. JAMA Cardiology, 2021, 6, 718.	3.0	7
47	Cardiac transplantation outcomes in patients with amyloid cardiomyopathy. American Heart Journal, 2021, 236, 13-21.	1.2	10
48	Equity and the JAMA Network. JAMA Health Forum, 2021, 2, e211638.	1.0	1
49	Preventable Deaths From Heart Disease and Stroke Among Racial and Ethnic Minorities in the United States. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007835.	0.9	4
50	Profile of Patients Hospitalized for Heart Failure Who Leave Against Medical Advice. Journal of Cardiac Failure, 2021, 27, 747-755.	0.7	3
51	Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelines–Heart Failure Hospitals. JAMA Cardiology, 2021, 6, 791.	3.0	14
52	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With HeartÂFailure. JACC: Heart Failure, 2021, 9, 471-481.	1.9	38
53	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 314.	3.8	68
54	Kidney Function and Outcomes in Patients Hospitalized With HeartÂFailure. Journal of the American College of Cardiology, 2021, 78, 330-343.	1.2	90

#	Article	IF	CITATIONS
55	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2021, 27, 826-836.	0.7	30
56	Optimizing the Potential for Telehealth in Cardiovascular Care (in the Era of COVID-19): Time Will Tell. American Journal of Medicine, 2021, 134, 945-951.	0.6	16
57	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e021459.	1.6	10
58	Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2021, 9, 876-886.	1.9	19
59	An Expanded Heart Failure Indication for Sacubitril/Valsartan. JAMA Cardiology, 2021, 6, 1357.	3.0	3
60	Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19. Circulation: Heart Failure, 2021, 14, e008354.	1.6	25
61	Diversity in Medical Schools—Need for a New Bold Approach. JAMA - Journal of the American Medical Association, 2021, 325, 31.	3.8	30
62	Risk-Based Intensive Blood Pressure Lowering and Prevention of Heart Failure: A SPRINT Post Hoc Analysis. Hypertension, 2021, 78, 1742-1749.	1.3	7
63	Fibroblast Growth Factor-23 and Subclinical Markers of Cardiac Dysfunction: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. American Heart Journal, 2021, 245, 10-10.	1.2	4
64	Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study. Frontiers in Cardiovascular Medicine, 2021, 8, 785109.	1.1	1
65	Change the Name of the Blalock-Taussig Shunt to Blalock-Thomas-Taussig Shunt. JAMA Surgery, 2021, , .	2.2	3
66	Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. JAMA Cardiology, 2020, 5, 292.	3.0	28
67	The Hospital Readmissions Reduction Program. JACC: Heart Failure, 2020, 8, 1-11.	1.9	57
68	Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines – Heart Failure Program). American Journal of Cardiology, 2020, 125, 894-900.	0.7	15
69	Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits After LVAD Placement?—A Call for a Randomized Clinical Trial. JAMA Cardiology, 2020, 5, 183.	3.0	1
70	Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort. Circulation: Heart Failure, 2020, 13, e007462.	1.6	17
71	Cancer therapy and the heart; the necessity to calibrate risk. European Journal of Heart Failure, 2020, 22, 1961-1965.	2.9	2
72	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. European Heart Journal, 2020, 41, 3363-3373.	1.0	103

#	Article	IF	CITATIONS
73	Improving Care for Heart Failure With Reduced Ejection Fraction—A Potential Polypill-Based Strategy. JAMA - Journal of the American Medical Association, 2020, 324, 2259.	3.8	18
74	Primer on Biomarker Discovery in Cardio-Oncology. JACC: CardioOncology, 2020, 2, 379-384.	1.7	14
75	Coronavirus Disease 2019 (COVID-19) and the Heart—Is Heart Failure the Next Chapter?. JAMA Cardiology, 2020, 5, 1216.	3.0	59
76	The Use of Sacubitril/Valsartan for Hospitalized Heart Failure—Why Do We Care About Cost and Value?. JAMA Cardiology, 2020, 5, 1244.	3.0	1
77	Trends in the Prevalence of Self-reported Heart Failure by Race/Ethnicity and Age From 2001 to 2016. JAMA Cardiology, 2020, 5, 1425.	3.0	28
78	The Critical Need for Process Improvement in Heart Failure. Heart Failure Clinics, 2020, 16, xiii-xv.	1.0	0
79	Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. JAMA Cardiology, 2020, 5, 1349.	3.0	13
80	Cardiology and COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1131.	3.8	41
81	Explanation for the Corrections for the Study of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1308.	3.0	2
82	Anticipating a New Era in Heart Transplantation. JAMA Cardiology, 2020, 5, 625.	3.0	2
83	Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiology, 2020, 5, 948.	3.0	77
84	COVID-19 and Katrina: recalcitrant racial disparities. European Heart Journal, 2020, 41, 3390-3393.	1.0	8
85	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. American Heart Journal, 2020, 226, 13-23.	1.2	7
86	Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiology, 2020, 5, 751.	3.0	471
87	Trends in Place of Death for Cardiovascular Mortality Related to Heart Failure in the United States From 2003 to 2017. Circulation: Heart Failure, 2020, 13, e006587.	1.6	15
88	Academic Medicine and Black Lives Matter. JAMA - Journal of the American Medical Association, 2020, 324, 435.	3.8	53
89	Distribution in Place of Death for <scp>COVID</scp> â€19–Related Mortality in the United States. Journal of the American Geriatrics Society, 2020, 68, 1917-1918.	1.3	10
90	Evaluating Biventricular Myocardial Velocity and Interventricular Dyssynchrony in Adult Patients During the First Year After Heart Transplantation. Journal of Magnetic Resonance Imaging, 2020, 52, 920-929.	1.9	1

#	Article	IF	CITATIONS
91	Heart Failure With Preserved Ejection Fraction and Obesity. JACC: Case Reports, 2020, 2, 28-32.	0.3	2
92	Endpoints in HeartÂFailure DrugÂDevelopment. JACC: Heart Failure, 2020, 8, 429-440.	1.9	28
93	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). American Journal of Cardiology, 2020, 125, 1655-1660.	0.7	7
94	Prognostic Value of Myocardial Extracellular Volume Fraction and T2-mapping in Heart Transplant Patients. JACC: Cardiovascular Imaging, 2020, 13, 1521-1530.	2.3	29
95	COVID-19 and African Americans. JAMA - Journal of the American Medical Association, 2020, 323, 1891.	3.8	1,609
96	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006645.	1.6	18
97	Contemporary Rates of Hospitalization for Heart Failure in Young and Middle-Aged Adults in a Diverse US State. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007014.	0.9	5
98	Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007094.	0.9	13
99	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. PLoS ONE, 2020, 15, e0240567.	1.1	4
100	Title is missing!. , 2020, 15, e0240567.		0
101	Title is missing!. , 2020, 15, e0240567.		0
102	Title is missing!. , 2020, 15, e0240567.		0
103	Title is missing!. , 2020, 15, e0240567.		0
104	Cardiac Structure–Function MRI in Patients After Heart Transplantation. Journal of Magnetic Resonance Imaging, 2019, 49, 678-687.	1.9	14
105	Impediments to Implementing Guideline-Directed Medical Therapies. JAMA Cardiology, 2019, 4, 830.	3.0	4
106	Pediatric Heart Transplantation: Transitioning to Adult Care (TRANSIT): Feasibility of a Pilot Randomized Controlled Trial. Journal of Cardiac Failure, 2019, 25, 948-958.	0.7	21
107	Ventricular Assist Device Driveline Dressing-Change Protocols: A Need for Standardization. A Report from the SimVAD Investigators. Journal of Cardiac Failure, 2019, 25, 695-697.	0.7	7
108	HeartÂFailure Management UnderÂPressure. Journal of the American College of Cardiology, 2019, 73, 3064-3066.	1.2	0

#	Article	IF	CITATIONS
109	Representativeness of a HeartÂFailure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	1.9	30
110	PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. Journal of Cardiac Failure, 2019, 25, 1009-1011.	0.7	5
111	Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines–Heart Failure Registry. American Heart Journal, 2019, 211, 1-10.	1.2	17
112	10-Year Risk Equations for Incident HeartÂFailure in the General Population. Journal of the American College of Cardiology, 2019, 73, 2388-2397.	1.2	107
113	Failure Is Not an Option. JACC: Heart Failure, 2019, 7, 558-560.	1.9	0
114	Association of the New Peer Group–Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. JAMA Network Open, 2019, 2, e192987.	2.8	42
115	Multiparametric Cardiac Magnetic Resonance Imaging Can Detect AcuteÂCardiac Allograft Rejection AfterÂHeart Transplantation. JACC: Cardiovascular Imaging, 2019, 12, 1632-1641.	2.3	60
116	Adrenergic Polymorphisms and Survival in African Americans With Heart Failure: Results From A-HeFT. Journal of Cardiac Failure, 2019, 25, 553-560.	0.7	5
117	Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. American Heart Journal, 2019, 212, 101-112.	1.2	18
118	Overcoming Lack of Diversity in Cardiovascular Clinical Trials. Circulation, 2019, 140, 1690-1692.	1.6	39
119	Donor and Recipient Characteristics in Heart Transplantation Are Associated with Altered Myocardial Tissue Structure and Cardiac Function. Radiology: Cardiothoracic Imaging, 2019, 1, e190009.	0.9	2
120	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118.	1.6	22
121	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines—Heart Failure. Journal of the American Heart Association, 2019, 8, e011560.	1.6	68
122	Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). American Journal of Cardiology, 2019, 123, 618-626.	0.7	5
123	Stopping medication for heart failure with improved ejection fraction. Lancet, The, 2019, 393, 8-10.	6.3	11
124	Heart Failure with Preserved Ejection Fraction in Women. Heart Failure Clinics, 2019, 15, 9-18.	1.0	33
125	Preparedness and Mutuality Affect Quality of Life for Patients With Mechanical Circulatory Support and Their Caregivers. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004414.	0.9	29
126	Pre-Ventricular Assist Device Palliative Care Consultation: A Qualitative Analysis. Journal of Pain and Symptom Management, 2019, 57, 100-107.	0.6	22

#	Article	IF	CITATIONS
127	Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges. European Journal of Heart Failure, 2019, 21, 286-296.	2.9	57
128	Fibroblast Growth Factor-23, Heart Failure Risk, and Renin–Angiotensin–Aldosterone-System Blockade in Hypertension: The MESA Study. American Journal of Hypertension, 2019, 32, 18-25.	1.0	15
129	World Heart Federation Roadmap for Heart Failure. Global Heart, 2019, 14, 197.	0.9	67
130	Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. Circulation: Heart Failure, 2018, 11, e004634.	1.6	20
131	Timing of Postdischarge Followâ€Up and Medication Adherence Among Patients With Heart Failure. Journal of the American Heart Association, 2018, 7, .	1.6	13
132	Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure WithÂPreserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 388-397.	1.9	21
133	Impact of Body Mass Index on Heart Failure by Race/Ethnicity From the Get WithÂThe Guidelines–Heart Failure (GWTG–HF) Registry. JACC: Heart Failure, 2018, 6, 233-242.	1.9	55
134	Evaluating Readmission—Need for More Clarity on Methods—Reply. JAMA Cardiology, 2018, 3, 265.	3.0	7
135	Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 288.	3.0	93
136	Pediatric Heart Transplantation: Transitioning to Adult Care (TRANSIT): Baseline Findings. Pediatric Cardiology, 2018, 39, 354-364.	0.6	14
137	A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. American Heart Journal, 2018, 200, 127-133.	1.2	13
138	Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines—Heart Failure. Journal of the American Heart Association, 2018, 7,	1.6	16
139	The TREAT Trial—Moving ST-Elevation Myocardial Infarction Care Forward, With More to Do. JAMA Cardiology, 2018, 3, 399.	3.0	2
140	Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization. JAMA Cardiology, 2018, 3, 489.	3.0	37
141	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. JAMA Cardiology, 2018, 3, 44.	3.0	346
142	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. Circulation, 2018, 137, 938-947.	1.6	17
143	Association of State Medicaid Expansion With Rate of Uninsured Hospitalizations for Major Cardiovascular Events, 2009-2014. JAMA Network Open, 2018, 1, e181296.	2.8	20
144	Cardiovascular Disease Disparities. JAMA Cardiology, 2018, 3, 1183.	3.0	4

9

#	Article	lF	CITATIONS
145	Sodium Restriction in Heart Failure: Too Much Uncertainty—Do the Trials. JAMA Internal Medicine, 2018, 178, 1700.	2.6	11
146	Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines–Heart Failure Registry. JAMA Cardiology, 2018, 3, 917.	3.0	50
147	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. American Heart Journal, 2018, 202, 97-103.	1.2	38
148	The New Hypertension Guidelines. JAMA Cardiology, 2018, 3, 581.	3.0	3
149	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. Circulation: Heart Failure, 2018, 11, e004646.	1.6	134
150	Buffer or Suffer. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004351.	0.9	4
151	Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004729.	0.9	31
152	The Current Landscape of AtrialÂFibrillation and Atrial Flutter ClinicalÂTrials. JACC: Clinical Electrophysiology, 2018, 4, 944-954.	1.3	5
153	Data Sharing—The Time Has (Not Yet?) Come. JAMA Cardiology, 2018, 3, 797.	3.0	3
154	Is Heart Failure Inherited?. JAMA Cardiology, 2018, 3, 710.	3.0	2
155	Vaccination Trends in Patients With HeartÂFailure. JACC: Heart Failure, 2018, 6, 844-855.	1.9	30
156	Strokes associated with left ventricular assist devices. Journal of Cardiac Surgery, 2018, 33, 578-583.	0.3	12
157	Association of Variants in <i>BAG3</i> With Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiology, 2018, 3, 929.	3.0	57
158	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology, 2018, 71, 2643-2652.	1.2	72
159	Addressing Cardiovascular Disease Disparities—Are We Getting Closer to the Truth?. JAMA Cardiology, 2018, 3, 748.	3.0	0
160	A common variant alters SCN5A–miR-24 interaction and associates with heart failure mortality. Journal of Clinical Investigation, 2018, 128, 1154-1163.	3.9	34
161	Relationship between Hospital 30â€Đay Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care. Journal of Hospital Medicine, 2018, 13, 170-176.	0.7	3
162	Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. American Journal of Cardiology, 2017, 119, 886-892.	0.7	9

#	Article	IF	CITATIONS
163	Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program― Circulation, 2017, 135, e22-e23.	1.6	2
164	Initiation, Continuation, or Withdrawal of Angiotensin onverting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	1.6	104
165	Contemporary Approaches to Patients with Heart Failure. Cardiology Clinics, 2017, 35, 261-271.	0.9	19
166	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With HeartÂFailure Eligible for Therapy. JACC: Heart Failure, 2017, 5, 388-392.	1.9	11
167	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017, 136, e137-e161.	1.6	2,130
168	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved EjectionÂFraction. JACC: Heart Failure, 2017, 5, 483-493.	1.9	41
169	The ICD and Shared Decision Making: Nothing Is Ever Easy. Journal of Cardiac Failure, 2017, 23, 800-801.	0.7	2
170	Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization. Circulation, 2017, 135, 2077-2080.	1.6	28
171	Claims Data to Ascertain Clinical Events. JAMA Cardiology, 2017, 2, 758.	3.0	3
172	New Blood Pressure–Lowering Targets—Finding Clarity. JAMA Cardiology, 2017, 2, 719.	3.0	7
173	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2017, 5, 305-309.	1.9	101
174	Reassessing Phase II Heart Failure Clinical Trials. Circulation: Heart Failure, 2017, 10, .	1.6	14
175	Acute Heart Failure. Journal of the American College of Cardiology, 2017, 69, 1420-1423.	1.2	6
176	Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2017, 2, 136.	3.0	50
177	The Hospital Readmission Reduction Program Is Associated With Fewer Readmissions, MoreÂDeaths. Journal of the American College of Cardiology, 2017, 70, 1931-1934.	1.2	79
178	Safety vs Efficacy of Lowering Blood Pressure—Reply. JAMA Cardiology, 2017, 2, 1400.	3.0	0
179	Author Relationships With Industry. JAMA Cardiology, 2017, 2, 1181.	3.0	0
180	Race/Ethnicity–Based Outcomes in Cardiovascular Medicine. JAMA Cardiology, 2017, 2, 1313.	3.0	5

#	Article	IF	CITATIONS
181	Usefulness of Coronary Artery Calcium to Predict Heart Failure With Preserved Ejection Fraction in Men Versus Women (from the Multi-Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2017, 120, 1847-1853.	0.7	21
182	Impaired Cardiac Function and Cognitive Brain Aging. Canadian Journal of Cardiology, 2017, 33, 1587-1596.	0.8	25
183	Heart Failure and Sudden Cardiac Death. Cardiac Electrophysiology Clinics, 2017, 9, 709-723.	0.7	21
184	Consequences of Reductions in Hospital Readmissions. JAMA - Journal of the American Medical Association, 2017, 318, 1933.	3.8	6
185	Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 2476-2486.	1.2	671
186	Incorporating Patient and Caregiver Experiences Into Cardiovascular Clinical Trial Design. JAMA Cardiology, 2017, 2, 1263.	3.0	11
187	Targeting the Correct Population When Designing Transitional Care Programs for Medicare Patients Hospitalized With Heart Failure. JAMA Cardiology, 2017, 2, 1274.	3.0	5
188	Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure. JAMA Cardiology, 2017, 2, 204.	3.0	249
189	Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. Journal of the American Heart Association, 2017, 6, .	1.6	32
190	Heart Failure—A New Phenotype Emerges. JAMA Cardiology, 2016, 1, 507.	3.0	16
191	Association of 30-Day Readmission MetricÂfor Heart Failure Under the HospitalÂReadmissions Reduction ProgramÂWith Quality of Care andÂOutcomes. JACC: Heart Failure, 2016, 4, 935-946.	1.9	68
192	Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure. JAMA Cardiology, 2016, 1, 163.	3.0	100
193	Stroke prevention in heart failure and sinus rhythm: where do we go from here?. European Journal of Heart Failure, 2016, 18, 1267-1269.	2.9	1
194	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure. Circulation, 2016, 134, 517-526.	1.6	90
195	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	127
196	2016 ESC and ACC/AHA/HFSA heart failure guideline update — what is new and why is it important?. Nature Reviews Cardiology, 2016, 13, 623-628.	6.1	38
197	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. Circulation: Heart Failure, 2016, 9, .	1.6	19
198	Hypertension, Obesity, Diabetes, andÂHeartÂFailure–Free Survival. JACC: Heart Failure, 2016, 4, 911-919.	1.9	96

#	Article	IF	CITATIONS
199	Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 757-766.	0.9	22
200	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	46
201	Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure. Current Atherosclerosis Reports, 2016, 18, 48.	2.0	10
202	Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. JAMA Cardiology, 2016, 1, 714.	3.0	89
203	Trends in the Use of Guideline-Directed TherapiesÂAmong Dialysis Patients HospitalizedÂWith Systolic Heart Failure. JACC: Heart Failure, 2016, 4, 649-661.	1.9	16
204	Reproducibility and observer variability of tissue phase mapping for the quantification of regional myocardial velocities. International Journal of Cardiovascular Imaging, 2016, 32, 1227-1234.	0.7	14
205	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. Circulation: Heart Failure, 2016, 9, e002630.	1.6	28
206	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	24
207	Clinical Effectiveness of Hydralazine–Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. Circulation: Heart Failure, 2016, 9, e002444.	1.6	29
208	Association of Arterial Pulse Pressure WithÂLong-Term Clinical Outcomes in Patients With Heart Failure. JACC: Heart Failure, 2016, 4, 42-49.	1.9	30
209	The Uncertainty of Sodium Restriction inÂHeart Failure. JACC: Heart Failure, 2016, 4, 39-41.	1.9	11
210	Worldwide disparities in cardiovascular disease: Challenges and solutions. International Journal of Cardiology, 2016, 202, 433-440.	0.8	55
211	Inâ€hospital worsening heart failure. European Journal of Heart Failure, 2015, 17, 1104-1113.	2.9	60
212	Length of hospital stay and 30â€day readmission following heart failure hospitalization: insights from the <scp>EVEREST</scp> trial. European Journal of Heart Failure, 2015, 17, 1022-1031.	2.9	52
213	Population Risk Prediction Models for Incident Heart Failure. Circulation: Heart Failure, 2015, 8, 438-447.	1.6	69
214	Health-related quality of life in mechanical circulatory support: Development of a new conceptual model and items for self-administration. Journal of Heart and Lung Transplantation, 2015, 34, 1292-1304.	0.3	29
215	Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 421-427.	0.9	22
216	Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization. Journal of the American Heart Association, 2015, 4, .	1.6	60

#	Article	IF	CITATIONS
217	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. American Heart Journal, 2015, 169, 305-314.	1.2	20
218	Extracellular Volume Fraction Is More Closely Associated With Altered Regional Left Ventricular Velocities Than Left Ventricular Ejection Fraction in Nonischemic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2015, 8, .	1.3	13
219	Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers. Future Oncology, 2015, 11, 2093-2103.	1.1	8
220	Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. JACC: Heart Failure, 2015, 3, 906-916.	1.9	54
221	Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 131, 269-279.	1.6	763
222	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. Journal of the American Heart Association, 2014, 3, e001098.	1.6	24
223	Disparate Care for Acute Myocardial Infarction. Circulation, 2014, 130, 632-633.	1.6	3
224	Short―and Longâ€ŧerm Rehospitalization and Mortality for Heart Failure in 4 Racial/Ethnic Populations. Journal of the American Heart Association, 2014, 3, e001134.	1.6	67
225	Impact of an Expanded Hospital Recognition Program for Heart Failure Quality of Care. Journal of the American Heart Association, 2014, 3, e000950.	1.6	11
226	Clinical Effectiveness of CRT and ICDÂTherapy in Heart Failure Patients byÂRacial/Ethnic Classification. Journal of the American College of Cardiology, 2014, 64, 797-807.	1.2	32
227	In Search of a Solution From theÂSTICHÂTriala^—. Journal of the American College of Cardiology, 2014, 64, 562-564.	1.2	0
228	C-Protein Beta-3 Subunit Genotype Predicts Enhanced Benefit of Fixed-Dose Isosorbide Dinitrate and Hydralazine. JACC: Heart Failure, 2014, 2, 551-557.	1.9	40
229	Nitrate Therapy for Heart Failure. JACC: Heart Failure, 2013, 1, 183-191.	1.9	28
230	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. JACC: Heart Failure, 2013, 1, 488-496.	1.9	58
231	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.	1.6	2,807
232	Cardiovascular disease outcomes: priorities today, priorities tomorrow for research and community health. Ethnicity and Disease, 2012, 22, S1-7-12.	1.0	1
233	Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. American Heart Journal, 2011, 161, 1024-1030.e3.	1.2	196
234	Incremental Value of Clinical Data Beyond Claims Data in Predicting 30-Day Outcomes After Heart Failure Hospitalization. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 60-67.	0.9	96

#	Article	IF	CITATIONS
235	Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction. Circulation, 2010, 121, 586-613.	1.6	3,508
236	Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2006, 296, 2217.	3.8	854
237	Affirming and Nurturing Students' Cultural Wealth to Enhance Self-efficacy: Examination of Urban High School Students' Lived Experiences in a STEM-Medicine Pipeline Program. Urban Education, 0, , 004208592110738.	1.2	5